Ascendis Pharma A/S (ASND) Financials

NASDAQ:ASND

Market Cap

5.51B

Total Revenue

51.17M

Gross Profit

39.04M

Operating Income

-561.81M

Net Income

-583.19M

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	20,408,000	13,983,000	8,118,000	4,606,000	1,530,000	10,581,000	13,375,000	6,953,000	7,778,000	51,174,000
costOfRevenue	--	--	--	--	--	--	--	--	3,523,000	12,137,000
grossProfit	20,408,000	13,983,000	8,118,000	4,606,000	1,530,000	10,581,000	13,375,000	6,953,000	4,255,000	39,037,000
researchAndDevelopmentExpenses	12,713,000	19,698,000	40,528,000	66,022,000	99,589,000	140,281,000	191,621,000	260,904,000	295,867,000	379,624,000
sellingAndMarketingExpenses	--	--	--	--	--	--	--	--	--	--
generalAndAdministrativeExpenses	2,416,000	6,274,000	9,415,000	11,504,000	13,482,000	25,057,000	48,473,000	--	--	--
sellingGeneralAndAdministrativeExpenses	2,416,000	6,274,000	9,415,000	11,504,000	13,482,000	25,057,000	48,473,000	76,669,000	160,180,000	221,227,000
operatingExpenses	15,129,000	25,972,000	49,943,000	77,526,000	113,071,000	165,338,000	240,094,000	337,573,000	456,047,000	600,851,000
operatingIncome	5,279,000	-11,989,000	-41,825,000	-72,920,000	-111,541,000	-154,757,000	-226,719,000	-330,620,000	-451,792,000	-561,814,000
totalOtherIncomeExpensesNet	-566,000	1,665,000	8,244,000	4,070,000	-13,659,000	20,373,000	8,469,000	-88,554,000	67,848,000	-16,003,000
ebitda	5,684,000	-11,485,000	-41,254,000	-72,120,000	-109,884,000	-150,178,000	-217,029,000	-328,884,000	-423,668,000	-527,330,000
depreciationAndAmortization	405,000	504,000	558,000	677,000	734,000	880,000	9,690,000	1,736,000	28,124,000	34,484,000
interestIncome	--	--	13,000	123,000	923,000	4,020,000	17,803,000	1,812,000	692,000	52,181,000
interestExpense	8,000	16,000	6,000	5,000	97,000	127,000	1,221,000	1,918,000	3,911,000	50,487,000
incomeBeforeTax	4,705,000	-10,340,000	-33,574,000	-68,732,000	-124,374,000	-130,491,000	-218,250,000	-419,174,000	-383,944,000	-577,817,000
incomeTaxExpense	626,000	-682,000	-652,000	-227,000	-477,000	-394,000	-234,000	-219,000	-367,000	5,377,000
netIncome	4,079,000	-9,658,000	-32,922,000	-68,505,000	-123,897,000	-130,097,000	-218,016,000	-418,955,000	-383,577,000	-583,194,000
eps	0.38	-0.57	-1.39	-2.58	-3.68	-3.17	-4.69	-8.28	-7	-10.4
epsdiluted	0.38	-0.57	-1.39	-2.58	-3.68	-3.17	-4.69	-8.28	-7	-10.4
weightedAverageShsOut	10,801,948	16,935,780	23,766,783	26,564,414	33,626,305	41,085,237	46,506,862	50,616,528	54,771,763	56,071,793
weightedAverageShsOutDil	10,801,948	16,935,780	23,766,783	26,564,414	33,626,305	41,085,237	46,506,862	50,616,528	54,771,763	56,071,793
costAndExpenses	15,129,000	25,972,000	49,943,000	77,526,000	113,071,000	165,338,000	240,094,000	337,573,000	459,570,000	612,988,000
otherExpenses	--	--	--	--	--	--	--	--	--	--

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

Hellerup, , DK

Website

ascendispharma.com

CEO

Mr. Jan Moller Mikkelsen

Employees

797

About the Company

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.